Startups
Established in 1958 and headquartered in Jinan, China, Qilu Pharmaceuticals is a large and comprehensive pharmaceutical company specializing in R&D, manufacture, sales and international trade of both APIs and drug products.
Overview
Location
China, Shandong, Jinan City
Employees
10001+
Founded date
1958
Mentions in press and media 21
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 13, 2026 | AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases | Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, setting a new record for the company's ann... |
| Sep 30, 2026 | Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist | CAMBRIDGE, Mass., Sept. 30, 2026 /PRNewswire/ -- As population aging accelerates with demand for weight management continuing to expand, the market for GLP-1 receptor agonist (GLP-1RA) drugs is experiencing explosive growth. Tirzepatide, wi... |
| Sep 17, 2026 | Insilico Medicine Opens AI Longevity Discovery Toolkit to Researchers Worldwide in Cell Cover Study | The paper introduces three interconnected resources for the global scientific community: LongevityBench, the first open benchmark designed to rigorously evaluate AI reasoning across multiple domains of aging biology; Longevity-LLMs, a famil... |
| Sep 17, 2026 | 111, Inc. Announces Second Quarter 2026 Unaudited Financial Results | Transition from An Asset-Heavy Business Model to An Asset-Light Business Model Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible Net Revenue of Promotional Products (1) Increased by 121% and Gross Profit Ro... |
| Sep 7, 2026 | Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks | First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). Firs... |
| Jul 24, 2026 | ArkBio Completes all Cohort Dosing in Australian Phase I Trial with Influenza AFC Drug AK0406 | SHANGHAI, July 24, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting ant... |
| Jul 9, 2026 | Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 | CAMBRIDGE, Mass., July 9, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" or the "Company", HKEX: 3696), a generative artificial intelligence (AI)-driven clinical-stage biotech company, today delivered a positive prof... |
| Jun 1, 2026 | Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting | HANGZHOU and SHANGHAI, China, June 1, 2026 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company focused on developing innovative therapies for oncology and autoimmune diseases, today ... |
| Sep 17, 2025 | Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI® (ALT-L9) | EYLUXVI® is the second biosimilar approved for Alteogen following the launch of the Herceptin® biosimilar in China through its partner Qilu Pharmaceutical. DAEJEON, South Korea, Sept. 17, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) a... |
Show more
Reviews 0
FAQ about Qilu Pharmaceutical
When was Qilu Pharmaceutical founded?
Qilu Pharmaceutical was founded in 1958.
What has the press written about Qilu Pharmaceutical?
Parsers VC has collected 21 articles mentioning Qilu Pharmaceutical, among them “AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases” (Oct 13, 2026) and “Breaking the Safety Barrier: Insilico Medicine Nominates ISM1354, the Next-Generation Small Molecule GIPR Antagonist” (Sep 30, 2026).
Is Qilu Pharmaceutical still active?
Yes, Qilu Pharmaceutical is active; its latest activity on Parsers VC dates from Oct 13, 2026.